Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
作者： Mina F. Nordness , Stephanie Hamel , Caroline M. Godfrey , Chanjuan Shi , Douglas B. Johnson
DOI: 10.1111/AJT.15617
关键词:
摘要: Nivolumab is an immune checkpoint inhibitor (ICI) currently in phase 3 clinical trials for hepatocellular carcinoma. The safety of ICIs recipients organ allotransplant unclear, and several reports fatal alloimmune injury after posttransplant ICI use have been published. We present the first published case nivolumab used pretransplant setting HCC resulting acute hepatic necrosis immediate postoperative period from a profound reaction likely propagated by nivolumab. Further investigation significant caution are needed evaluation patients awaiting transplant who receiving therapy.
sci-hub.se 参考文章(18)
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian, Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Journal of Clinical Oncology. ,vol. 28, pp. 3167- 3175 ,(2010) , 10.1200/JCO.2009.26.7609
J.M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, A. Berdelou, A. Varga, R. Bahleda, A. Hollebecque, C. Massard, A. Fuerea, V. Ribrag, A. Gazzah, J.P. Armand, N. Amellal, E. Angevin, N. Noel, C. Boutros, C. Mateus, C. Robert, J.C. Soria, A. Marabelle, O. Lambotte, Immune-related adverse events with immune checkpoint blockade: a comprehensive review European Journal of Cancer. ,vol. 54, pp. 139- 148 ,(2016) , 10.1016/J.EJCA.2015.11.016
Xiao-Lei Shi, Shanta Mancham, Bettina E. Hansen, Robert J. de Knegt, Jeroen de Jonge, Luc J.W. van der Laan, Fernando Rivadeneira, Herold J. Metselaar, Jaap Kwekkeboom, Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction Journal of Hepatology. ,vol. 64, pp. 1274- 1282 ,(2016) , 10.1016/J.JHEP.2016.02.034
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling, Tim Meyer, Yoon-Koo Kang, Winnie Yeo, Akhil Chopra, Jeffrey Anderson, Christine dela Cruz, Lixin Lang, Jaclyn Neely, Hao Tang, Homa B Dastani, Ignacio Melero, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial The Lancet. ,vol. 389, pp. 2492- 2502 ,(2017) , 10.1016/S0140-6736(17)31046-2
Brian D. Friend, Robert S. Venick, Sue V. McDiarmid, Xiaoyan Zhou, Bita Naini, Hanlin Wang, Douglas G. Farmer, Ronald W. Busuttil, Noah Federman, Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatric Blood & Cancer. ,vol. 64, ,(2017) , 10.1002/PBC.26682
Ashwin Rammohan, Mettu S Reddy, Mohammed Farouk, Joy Vargese, Mohamed Rela, None, Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet? Hepatology. ,vol. 67, pp. 1166- 1168 ,(2018) , 10.1002/HEP.29575
I. Puzanov, , A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman, M. S. Ernstoff, Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group Journal for ImmunoTherapy of Cancer. ,vol. 5, pp. 95- 95 ,(2017) , 10.1186/S40425-017-0300-Z
Michael A. Postow, Robert Sidlow, Matthew D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade The New England Journal of Medicine. ,vol. 378, pp. 158- 168 ,(2018) , 10.1056/NEJMRA1703481
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura D. Porter, Igor Puzanov, Cristina A. Reichner, Bianca D. Santomasso, Carole Seigel, Alexander Spira, Maria E. Suarez-Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson, , Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Journal of Clinical Oncology. ,vol. 36, pp. 1714- 1768 ,(2018) , 10.1200/JCO.2017.77.6385
Antoni Ribas, Jedd D. Wolchok, Cancer immunotherapy using checkpoint blockade Science. ,vol. 359, pp. 1350- 1355 ,(2018) , 10.1126/SCIENCE.AAR4060